Results 51 to 60 of about 2,008,123 (283)

Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer

open access: yesBMC Medical Imaging, 2021
Background Human epidermal growth factor receptor2+ subtype breast cancer has a high degree of malignancy and a poor prognosis. The aim of this study is to develop a prediction model for the human epidermal growth factor receptor2+ subtype (non-luminal ...
Jin Zhou   +9 more
doaj   +1 more source

Epidermal growth factor-induced truncation of the epidermal growth factor receptor

open access: yesJournal of Biological Chemistry, 1989
NIH-3T3 cells expressing the human epidermal growth factor (EGF) receptor were used in experiments to determine the fate of the EGF receptor in cells continuously exposed to EGF. EGF receptor was immunoprecipitated from cells labeled for 12 h with [35S] methionine in the absence or presence of 10 nM EGF.
openaire   +3 more sources

Epidermal growth factor receptor signaling [PDF]

open access: yesCurrent Biology, 2001
Inhibitory signaling is an important way of fine tuning EGFR activity to enable a cell to discriminate between short and prolonged exposure to signaling molecules. Over the last few years a number of different mechanisms have been shown to abrogate receptor activity (Fig. 3Fig. 3). First, inhibitory signaling molecules are expressed in response to EGFR
Christian Klämbt, Sven Bogdan
openaire   +3 more sources

Specific Rab GTPase-activating proteins define the Shiga toxin and epidermal growth factor uptake pathways [PDF]

open access: yes, 2007
Rab family guanosine triphosphatases (GTPases) together with their regulators define specific pathways of membrane traffic within eukaryotic cells. In this study, we have investigated which Rab GTPase-activating proteins (GAPs) can interfere with the ...
Barr, Francis A.   +5 more
core   +2 more sources

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

open access: yesThoracic Cancer, 2021
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi   +10 more
doaj   +1 more source

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death [PDF]

open access: yes, 2017
Although inhibition of the epidermal growth factor receptor is a plausible therapy for malignant gliomas that, in vitro, enhances apoptosis, the results of clinical trials have been disappointing.
Brucker, Daniel P.   +8 more
core  

Dynamic tracing for epidermal growth factor receptor mutations in urinary circulating DNA in gastric cancer patients

open access: yesTumor Biology, 2017
The mutations of epidermal growth factor receptor are detected in gastric cancer, indicating its suitability as a target for receptor tyrosine kinase inhibitors, as well as a marker for clinical outcome of chemotherapeutic treatments. However, extraction
Xiu-Qin Shi   +4 more
doaj   +1 more source

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma

open access: yesSAGE Open Medical Case Reports, 2023
A 71-year-old non-smoker woman was admitted to our hospital because of left front chest pain. A computed tomography scan showed a large mass of >7.0 cm in the lower left part of the lung and multiple organ metastases in the liver, brain, bone, and left ...
Sosuke Matsumura   +7 more
doaj   +1 more source

Immunohistochemical study of epidermal growth factor and epidermal growth factor receptor in gastric carcinoma [PDF]

open access: yesCancer, 1989
Immunohistochemical study for epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) was performed on 222 specimens of gastric carcinoma. The authors placed each carcinoma into one of the following three groups: group 1, neither EGF nor EGFR was stained (123 cases); group 2, either EGF or EGFR was stained (64 cases); and group 3 ...
Sugiyama K   +2 more
openaire   +3 more sources

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy [PDF]

open access: yes, 2017
Introduction: Clinical guidelines have recommended a 1-year trastuzumab regimen as standard care for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer; however ...
Ansaripour, A. (Amir)   +2 more
core   +4 more sources

Home - About - Disclaimer - Privacy